This Viewpoint discusses artificial intelligence for treatment of diabetic retinopathy.
| # | Наименование новости | Тональность | Информативность | Дата публикации |
|---|---|---|---|---|
| 1 | Dry Eye Disease Therapies at a Crossroads | 0 | 6.4 | 17-09-2026 |
| 2 | Ultra–Long-Distance Robotic-Assisted Subretinal Injection for Submacular Hemorrhage | 0 | 16.79 | 20-08-2026 |
| 3 | AI in Action | 0 | 10 | 14-08-2026 |
| 4 | Empagliflozin and the Risk of Retinopathy in Type 2 Diabetes | 0 | 11.22 | 01-01-2025 |
| 5 | Digital Defocus Vision Training Using Virtual Reality for Myopia Control | 0 | 9.14 | 27-08-2026 |
| 6 | Event-Based Progression Detection Among OCT, OCTA, and VF in Glaucoma | 0 | 9.28 | 03-09-2026 |
| 7 | Highly Aspherical Lenslets for Myopia Control | 0 | 6.82 | 20-08-2026 |
| 8 | AI Governance Tracker | 0 | 10 | 24-06-2026 |
| 9 | rTG ω-3 Fatty Acids in Dry Eye Disease With MGD | 0 | 8 | 01-07-2024 |
| 10 | Language in the age of AI: Whimsymaxxing the apocalypse | 0 | 8.1 | 25-09-2026 |